Adalimumab
Brand: Humira®
NICE TA: 392
Indication: Treating moderate to severe hidradenitis suppurativa (NICE TA392)
Disease category: Skin
Commissioning responsibility: NHS England
PbR excluded: Yes
Background
Adalimumab is recommended, within its marketing authorisation, as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy. The drug is recommended only if the company provides it at the price agreed in the patient access scheme.
Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as:
• a reduction of 25% or more in the total abscess and inflammatory nodule count and
• no increase in abscesses and draining fistulas.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
NICE TA392 - Adalimumab for treating moderate to severe hidradenitis suppurativa
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
